Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Letters|August 31, 2018
Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biologyChangju Qu, Kranthi Kunkalla, Amineh Vaghefi, et al.
Cancer Research|December 8, 2010
14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stabilityChun-Hui Su, Ruiying Zhao, Fanmao Zhang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2019
Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor BurdenChangju Qu, Nana Ping, Liqing Kang, et al.
Bone Marrow Transplantation|February 27, 2021
Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantationXiaowen Tang, Benigno C Valdez, Yunju Ma, et al.
Hematology (Amsterdam, Netherlands)|April 12, 2022
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphomaLihong Zhang, Haifei Yang, Chongsheng Qian, et al.
Leukemia Research|July 20, 2012
Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphomaElisa Ramirez, Rajesh R Singh, Kranthi Kunkalla, et al.
Journal of Hematology & Oncology|May 26, 2021
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationQingya Cui, Chongsheng Qian, Nan Xu, et al.
JCI Insight|July 24, 2019
Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphomaCaixia Li, Ying Zhang, Changfeng Zhang, et al.
The Journal of Clinical Investigation|February 15, 2011
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancersRuiying Zhao, Sai-Ching J Yeung, Jian Chen, et al.
Journal of Hematology & Oncology|April 2, 2022
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cellsJingwen Tan, Yujie Jia, Meixia Zhou, et al.
Pageof 3